Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?

NCT ID: NCT01279330

Last Updated: 2011-01-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1569 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The propose of this study is to assess the effect of general practitioner's involvement in the stimulus invitation letter in colorectal cancer screening compared to sending the patient home test (stimulus 2 of reference as contained in the specifications).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Patients receive by mail the materials needed for stool samples.

Group Type NO_INTERVENTION

Control

Intervention Type OTHER

No intervention (Patients receive by mail the materials needed for stool samples).

Co-signed Letter

Group Type EXPERIMENTAL

Co-signed Letter

Intervention Type OTHER

Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Co-signed Letter

Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.

Intervention Type OTHER

Control

No intervention (Patients receive by mail the materials needed for stool samples).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age : 50 to 74 years.
* Not having answered the first two solicitations of ADECA75 to participate in screening for colorectal cancer

Exclusion Criteria

* Patients who have a Fecal Occult Blood Test for less than 2 years or a colonoscopy within the past 5 years or excluded for medical reasons (according to information known from ADECA).
Minimum Eligible Age

50 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Adeca 75

OTHER

Sponsor Role collaborator

Société de Formation Thérapeutique du Généraliste

OTHER

Sponsor Role collaborator

Hotel Dieu Hospital

OTHER

Sponsor Role collaborator

University of Paris 5 - Rene Descartes

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Université Paris Descartes - Département de Médecine Générale

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Université Paris Descartes

Paris, Île-de-France Region, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Serge Gilberg

Role: CONTACT

01 44 41 23 63

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Barthe

Role: primary

01 44 41 23 63

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAGEDOCC2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.